Vidya Vasu-Devan

By developing novel and affordable vaccines for all populations worldwide were addressing health inequalities and empowering people to live healthy lives Inventprise is a mission driven vaccine manufacturing company developing vaccines that have shown a more robust and broader spectrum of protection than currently marketed conjugated vaccines. Our lead vaccine candidate is a 25-valent pneumococcal conjugate vaccine (PCV) funded by the Bill and Melinda Gates Foundation (>$100M) and aimed at large-scale supply to Low-Middle Income Countries. Additionally, we have a robust pipeline of vaccines and vaccine technologies, that have both viral and bacterial applications. Inventprise was founded in 2012, and is led by founder and Executive Chairman, Subhash Kapre PhD, former SVP and Corporate Officer of Serum Institute of India and Chief Executive Officer, Yves Leurquin, former general manager of Takeda Vaccines, Europe. Inventprise is based in Redmond, Washington, we have over 100,000 square feet of recently built, state-of-the-art facilities that have the capacity for large scale volume (>150M annual doses). With over 100 employees mostly exceptionally qualified industry scientists, and manufacturing professionals, Inventprise has created a large and dynamic presence in the Washington State Life Sciences environment.

Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com

AgBiome® partners with the microbial world to improve our planet. AgBiome discovers and develops innovative biological and trait products for crop protection. The proprietary GENESIS™ discovery platform efficiently captures diverse, unique microbes for agriculturally relevant applications, and screens them with industry-best assays for insect, disease, and nematode control. Through its commercial subsidiary, AgBiome develops and sells proprietary crop protection solutions. The first of these, Howler®, is a revolutionary fungicide for disease control in a broad variety of crops.

Founded in 2011, M-KOPA is a fintech platform that provides digital financial services to underbanked consumers by leveraging data to combine digital micropayments with the Internet of Things [IoT] technology. With operations in Kenya, Uganda, Nigeria and Ghana, M-KOPA’s platform has provided over $1 billion in credit and enabled 3 million customers to access smartphones, electric motorcycles, solar power systems, digital loans and health insurance. The company directly employs nearly 2,000 people across Africa and has created over 10,000 roles for sales agents since the start of 2020.

GHIC is an impact investment firm that has been a pioneer in structuring, managing and investing in transformative funds to improve global health. Our namesake Global Health Investment Fund raised $108 million from leading global health stakeholders and investors, and invested in twelve companies developing products focused on global health challenges that disproportionately burden people living in low- and middle- income countries. The fund’s portfolio companies have more than a dozen registered products that have positively impacted over 100 million lives globally. GHIC, a 501c4 charitable corporation, has recently expanded its mission to also include a focus on global health security and pandemic preparedness.

By developing novel and affordable vaccines for all populations worldwide were addressing health inequalities and empowering people to live healthy lives Inventprise is a mission driven vaccine manufacturing company developing vaccines that have shown a more robust and broader spectrum of protection than currently marketed conjugated vaccines. Our lead vaccine candidate is a 25-valent pneumococcal conjugate vaccine (PCV) funded by the Bill and Melinda Gates Foundation (>$100M) and aimed at large-scale supply to Low-Middle Income Countries. Additionally, we have a robust pipeline of vaccines and vaccine technologies, that have both viral and bacterial applications. Inventprise was founded in 2012, and is led by founder and Executive Chairman, Subhash Kapre PhD, former SVP and Corporate Officer of Serum Institute of India and Chief Executive Officer, Yves Leurquin, former general manager of Takeda Vaccines, Europe. Inventprise is based in Redmond, Washington, we have over 100,000 square feet of recently built, state-of-the-art facilities that have the capacity for large scale volume (>150M annual doses). With over 100 employees mostly exceptionally qualified industry scientists, and manufacturing professionals, Inventprise has created a large and dynamic presence in the Washington State Life Sciences environment.

Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com

AgBiome® partners with the microbial world to improve our planet. AgBiome discovers and develops innovative biological and trait products for crop protection. The proprietary GENESIS™ discovery platform efficiently captures diverse, unique microbes for agriculturally relevant applications, and screens them with industry-best assays for insect, disease, and nematode control. Through its commercial subsidiary, AgBiome develops and sells proprietary crop protection solutions. The first of these, Howler®, is a revolutionary fungicide for disease control in a broad variety of crops.